{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"submitter":["Marie Rumpler"],"organism":["Mus musculus"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-14177"],"description":["NAD+ is a crucial cofactor for the activity of various enzymes, including sirtuins and ADP-ribosyl transferases, and its decline is associated with aging and metabolic-related diseases. Therefore, a strong interest has been raised in the therapeutic use of NAD+ precursors (Vitamin B3s), but many suffer from poor bioavailability and adverse effects. This study characterizes the metabolic impact of dihydronicotinamide riboside, a recently identified novel form of NAD+ precursor. Upon oral administration in mice, NRH reaches all tissues examined. Chronic administration in low-fat diet-fed mice showed negligible metabolic effects, while high-fat diet-fed mice were protected against body weight gain and glucose intolerance. However, our study also unveiled potential side effects at higher doses. Thus, NRH could constitute an alternative NAD+ boosting strategy to prevent diet-induced metabolic complications and conditions associated with low NAD+ levels, but the therapeutic window must be optimized to maximize benefits and minimize risks."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Nucleic Acid Extraction - DNA from mouse feces samples were obtained using a Quick-DNA Fecal/Soil Microbe Miniprep Kit from Zymo (#D6010).","Library Construction - Libraries were generated using a \\\\\"16S library prep with ZYMO Quick-16S_Plus\\\\\" library prep kit according to manufacturers’ instructions. Libraries have been pooled prior to sequencing and quantified by a qubit DNA High Sensitivity assay (Thermo, #Q32851).","Sequencing - The pooled library was sequencing on an Illumina MiSeq using 300 PE sequencing chemistry.","Sample Collection - Male and Female C57Bl/6NTac were purchased from Taconic. All mice were kept in a standard temperature- and humidity-controlled environment with a 12h:12h light-dark cycle. Mice had nesting material and ad libitum access to water and commercial diets. For the control diet (chow), mice were fed a regular mouse housing diet (Safe®150)."],"figure_sub":["Organization","MINSEQE Score","Assays and Data","Processed Data","MAGE-TAB Files"],"data_protocol":["Data Transformation - Data preprocessing was done using DADA2 (Callahan, Nature Methods, 2016). Downstream analysis was performed using Phyloseq (McMurdie, Plos One, 2013).","Sequence Alignment - Data preprocessing was done using DADA2 (Callahan, Nature Methods, 2016)."],"omics_type":["Metabolomics","Unknown","Transcriptomics","Genomics","Proteomics"],"instrument_platform":["Illumina MiSeq"],"study_type":["DNA-seq"],"species":["Mus musculus"],"pubmed_authors":["Marie Rumpler","Julie Russeil","Sofia Moco","Carles Canto","Bart Deplancke","Faisal Hayat","Stefan Christen","Vincent Gardeux","Horia Hashimi","Clémence Steiner","Judith Giroud-Gerbetant","Maria Pilar Giner","Riekelt Houtkooper","Kasper Vinten","Magali Joffraud","Jose Luis Sanchez Garcia","Marie Migaud","Guido Van Mierlo","Laurine Van Gijn"],"additional_accession":[]},"is_claimable":false,"name":"Metabolic effects of chronic dihydronicotinamide riboside (NRH) administration in mice - Microbiome 16S rRNA sequencing of murine feces (NRH treatment)","description":"NAD+ is a crucial cofactor for the activity of various enzymes, including sirtuins and ADP-ribosyl transferases, and its decline is associated with aging and metabolic-related diseases. Therefore, a strong interest has been raised in the therapeutic use of NAD+ precursors (Vitamin B3s), but many suffer from poor bioavailability and adverse effects. This study characterizes the metabolic impact of dihydronicotinamide riboside, a recently identified novel form of NAD+ precursor. Upon oral administration in mice, NRH reaches all tissues examined. Chronic administration in low-fat diet-fed mice showed negligible metabolic effects, while high-fat diet-fed mice were protected against body weight gain and glucose intolerance. However, our study also unveiled potential side effects at higher doses. Thus, NRH could constitute an alternative NAD+ boosting strategy to prevent diet-induced metabolic complications and conditions associated with low NAD+ levels, but the therapeutic window must be optimized to maximize benefits and minimize risks.","dates":{"release":"2026-03-09T00:00:00Z","modification":"2026-03-09T02:02:49.789Z","creation":"2024-06-13T09:22:09.365Z"},"accession":"E-MTAB-14177","cross_references":{"ENA":["ERP161083"],"EFO":["EFO_0002944","EFO_0004170","EFO_0002693","EFO_0004917","EFO_0005518","EFO_0003816","EFO_0004184"]}}